全文获取类型
收费全文 | 28196篇 |
免费 | 4212篇 |
国内免费 | 285篇 |
专业分类
耳鼻咽喉 | 824篇 |
儿科学 | 907篇 |
妇产科学 | 729篇 |
基础医学 | 2657篇 |
口腔科学 | 509篇 |
临床医学 | 3847篇 |
内科学 | 5730篇 |
皮肤病学 | 807篇 |
神经病学 | 3042篇 |
特种医学 | 1007篇 |
外国民族医学 | 5篇 |
外科学 | 5038篇 |
综合类 | 175篇 |
现状与发展 | 2篇 |
一般理论 | 14篇 |
预防医学 | 2955篇 |
眼科学 | 618篇 |
药学 | 1271篇 |
中国医学 | 14篇 |
肿瘤学 | 2542篇 |
出版年
2023年 | 707篇 |
2022年 | 325篇 |
2021年 | 1112篇 |
2020年 | 1156篇 |
2019年 | 1001篇 |
2018年 | 1504篇 |
2017年 | 1223篇 |
2016年 | 1417篇 |
2015年 | 1383篇 |
2014年 | 1865篇 |
2013年 | 2122篇 |
2012年 | 2006篇 |
2011年 | 1927篇 |
2010年 | 1440篇 |
2009年 | 1540篇 |
2008年 | 1454篇 |
2007年 | 1321篇 |
2006年 | 1309篇 |
2005年 | 1115篇 |
2004年 | 985篇 |
2003年 | 771篇 |
2002年 | 708篇 |
2001年 | 236篇 |
2000年 | 171篇 |
1999年 | 233篇 |
1998年 | 381篇 |
1997年 | 348篇 |
1996年 | 369篇 |
1995年 | 333篇 |
1994年 | 229篇 |
1993年 | 168篇 |
1992年 | 151篇 |
1991年 | 152篇 |
1990年 | 82篇 |
1989年 | 148篇 |
1988年 | 117篇 |
1987年 | 89篇 |
1986年 | 100篇 |
1985年 | 98篇 |
1984年 | 102篇 |
1983年 | 87篇 |
1982年 | 82篇 |
1981年 | 57篇 |
1980年 | 65篇 |
1979年 | 32篇 |
1978年 | 51篇 |
1977年 | 50篇 |
1976年 | 45篇 |
1975年 | 48篇 |
1972年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 450 毫秒
1.
Kienbaum Peter Schaefer Maximilian S. Weibel Stephanie Schlesinger Tobias Meybohm Patrick Eberhart Leopold H. Kranke Peter 《Der Anaesthesist》2022,71(2):123-128
Die Anaesthesiologie - Auch wenn für Anästhesiologen über Jahrzehnte die Prophylaxe und Therapie postoperativer Schmerzen im Rahmen des postoperativen Patientenkomforts an vorderster... 相似文献
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
4.
5.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
6.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
7.
8.
9.
Stephanie Kay Kolar 《Addiction Research & Theory》2016,24(1):25-31
Aims: Relapse rates among cigarette smokers are high. Few studies have examined time-to-relapse using survival analysis in racially/ethnically diverse smokers and initial abstinence criteria have been inconsistent or unspecified. This study compared survival curves using two common definitions of initial abstinence. We hypothesized greater relapse rates among participants abstinent for only 24 hours (h) at the end-of-therapy (EOT) compared with 7 days. Methods: Adult smokers (59% Black, 22% Hispanic and 17% White) received 8-sessions of group cognitive behavioural therapy (CBT) plus transdermal nicotine patches and were assessed monthly up to 12 months post-EOT. Participants reporting abstinence (7-day point prevalence abstinence [ppa] or 24-h ppa) at the EOT were included in Kaplan–Meier curves. Results: Of 301 participants, 120 (40%) reported 7-day ppa at the EOT and an additional 29 (10%) reported 24-h ppa only. Over the 12-month follow-up period, nearly 50% remained abstinent. Of those who resumed smoking, most relapses occurred within the first three months. Survival curves indicated that median survival was 207 and 225 days for 7-day and 24-h definitions of abstinence, respectively. The difference in time-to-relapse between participants abstinent for 24?h at the EOT versus 7-days was not significant (p?=?0.14). Conclusions: Operationalization of initial abstinence is important for relapse analyses and comparisons of survival curves across samples. Participants reported high rates of abstinence and relapse rates were relatively low. Contrary to expectations, 24-h ppa at the EOT was not associated with greater relapse than 7-day abstinence. This suggests either measure may be utilized in relapse prevention research in racially/ethnically diverse treatment-seekers. 相似文献
10.
Bhavana Pothuri Allison L. Brodsky Joseph A. Sparano Stephanie V. Blank Mimi Kim Dawn L. Hershman Amy Tiersten Brian F. Kiesel Jan H. Beumer Leonard Liebes Franco Muggia 《Cancer chemotherapy and pharmacology》2020,85(4):741-751
Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in breast and recurrent gynecologic cancer patients. Veliparib and PLD were administered in a standard phase 1, 3 + 3 dose-escalation design starting at 50 mg veliparib BID on days 1–14 with PLD 40 mg/mg2 on day 1 of a 28-day cycle. Dose escalation proceeded in two strata: A (prior PLD exposure) and B (no prior PLD exposure). Patients underwent limited pharmacokinetic (PK) sampling; an expansion PK cohort was added. 44 patients with recurrent ovarian or triple negative breast cancer were enrolled. Median age 56 years; 23 patients BRCA mutation carriers; median prior regimens four. Patients received a median of four cycles of veliparib/PLD. Grade 3/4 toxicities were observed in 10% of patients. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. Two BRCA mutation carriers had complete responses. Two BRCA patients developed oral squamous cell cancers after completing this regimen. PLD exposure was observed to be higher when veliparib doses were > 200 mg BID. The RP2D is 200 mg veliparib BID on days 1–14 with 40 mg/m2 PLD on day 1 of a 28-day cycle. Anti-tumor activity was seen in both strata. However, given development of long-term squamous cell cancers and the PK interaction observed, efforts should focus on other targeted combinations to improve efficacy. 相似文献